As Baxter gets ready to transition out its pharma portfolio into a freestanding company, the pharma's venture arm is teaming up with the Mayo Clinic and Velocity Pharmaceutical Development to create a new early-stage biotech dubbed Vitesse Biologics.
The biotech will focus on hematology, immunology and oncology with each of the contributing entities providing their expertise to help...






